SEC 13F Intelligence

Altium Capital Management LLC / NBIX

Altium Capital Management LLC’s Neurocrine Biosciences Inc Position

Does Altium Capital Management LLC own Neurocrine Biosciences Inc (NBIX)? Not currently — the last reported position was 17.5K shares worth $2M in Q4 2022; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$2M
Q4 2022
Shares
17.5K
% of Portfolio
+1.06%
Quarters Held
3
position exited

Position History NBIX

Reported value by quarter
Q2 ’22: $2MQ2 ’22Q3 ’22: $2MQ3 ’22Q4 ’22: $2MQ4 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q4 202217.5K$2M+1.06%
Q3 202219.0K$2M+0.74%
Q2 202222.0K$2M+0.86%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Altium Capital Management LLC’s full portfolio or all institutional holders of NBIX.